Engene reports full year 2024 financial results and provides a business update

Boston & montreal--(business wire)--engene holdings inc. (nasdaq: engn, or “engene” or the “company”), a clinical-stage genetic medicines company whose non-viral lead investigational product detalimogene voraplasmid, (also known as detalimogene, and previously eg-70), is in an ongoing pivotal study in patients with high-risk, bacillus calmette-guÉrin (bcg)-unresponsive, non-muscle invasive bladder cancer (nmibc) with carcinoma in situ (cis), announced its financial results for the full year end.
ENGN Ratings Summary
ENGN Quant Ranking